MediWound VP discloses initial equity holdings
MediWound Ltd. VP Clinical & Reg.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
MediWound Ltd. VP Clinical & Reg. Affairs Aya Ben Yaakov filed an initial Form 3 reporting existing equity holdings in the company. The filing lists several stock options to buy ordinary shares at exercise prices between 12.25 and 37.52 with expirations from 2028 to 2036, plus ordinary shares, including amounts underlying RSUs. Footnotes explain that these RSUs and options vest over four years, with 25% vesting after one year and 6.25% vesting quarterly thereafter. The filing shows holdings only, without any reported purchases or sales.
Insider Trade Summary
11 transactions reported
Mixed
11 txns
Insider
Ben Yaakov Aya
Role
VP Clinical & Reg. Affairs
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Ordinary shares | -- | -- | -- |
| holding | Ordinary shares | -- | -- | -- |
| holding | Ordinary shares | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy ordinary shares) — 28,239 contracts (Direct);
Ordinary shares — 2,357 shares (Direct)
Footnotes (7)
- F1. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on February 15, 2023 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
- F2. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
- F3. The options reported in this row were granted to the Reporting Person on May 16, 2022 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
- F4. The options reported in this row were granted to the Reporting Person on February 15, 2023 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
- F5. The options reported in this row were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
- F6. The options reported in this row were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
- F7. The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does MediWound (MDWD) VP Aya Ben Yaakov report in this Form 3?
Aya Ben Yaakov reports her initial equity holdings in MediWound, including stock options and ordinary shares. The filing details multiple option grants and RSU-based holdings, giving investors a snapshot of her compensation-linked stake at the time of becoming a reporting insider.
Are there any stock purchases or sales reported for MDWD in this Form 3?
No purchases or sales are reported; the Form 3 only lists existing holdings. It shows stock options and ordinary shares, including RSU-based amounts, as of the reporting date. This is a baseline ownership disclosure rather than a record of new trading activity in MediWound shares.
What stock options does the MediWound VP hold according to the Form 3?
The VP holds several stock options to buy MediWound ordinary shares, with exercise prices such as 36.0500, 12.2500, 37.5200, 14.4200, 13.3200, 12.7290, 18.5400, and 17.6000. These options expire between 2028 and 2036, reflecting multiple annual equity grants over recent years.
How do the MediWound RSUs granted to Aya Ben Yaakov vest?
Footnotes state the RSUs vest over four years: 25% vests on the first anniversary of the grant date, then 6.25% vests quarterly for three more years. This schedule applies to RSUs granted on February 15, 2023 and March 4, 2026, aligning vesting with multi-year service.
What is the vesting schedule for MediWound stock options held by the VP?
The options granted on May 16, 2022, February 15, 2023, February 26, 2024, February 11, 2025, and March 4, 2026 vest over four years. For each grant, 25% vests after one year, then 6.25% vests quarterly over the next three years until fully vested.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates